Cargando…
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
AIMS: Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF). Uninterrupted edoxaban therapy in patients undergoing AF ablation has not been tested. METHODS AND RESULTS: The ELIMINATE-AF trial, a multinational, multicentre, randomized, open-label, paralle...
Autores principales: | Hohnloser, Stefan H, Camm, John, Cappato, Riccardo, Diener, Hans-Christoph, Heidbüchel, Hein, Mont, Lluís, Morillo, Carlos A, Abozguia, Khalid, Grimaldi, Massimo, Rauer, Heiko, Reimitz, Paul-Egbert, Smolnik, Rüdiger, Mönninghoff, Christoph, Kautzner, Josef |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754569/ https://www.ncbi.nlm.nih.gov/pubmed/30976787 http://dx.doi.org/10.1093/eurheartj/ehz190 |
Ejemplares similares
-
Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
por: Hohnloser, Stefan H, et al.
Publicado: (2020) -
The First Venomous Crustacean Revealed by Transcriptomics and Functional Morphology: Remipede Venom Glands Express a Unique Toxin Cocktail Dominated by Enzymes and a Neurotoxin
por: von Reumont, Björn M., et al.
Publicado: (2014) -
Fitness Landscape of the Fission Yeast Genome
por: Grech, Leanne, et al.
Publicado: (2019) -
Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial
por: Haldar, Shouvik, et al.
Publicado: (2020) -
Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial
por: Willems, Stephan, et al.
Publicado: (2021)